S hares of Inogen (INGN) have been struggling lately and have lost 6.7% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock ...

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to ...

Inogen, Inc. INGN is well-poised for growth in the coming quarters, courtesy of high prospects in the portable oxygen concentrator (POC) space. The optimism, led by solid fourth-quarter 2024 ...

Inogen stock opened at $8.33 on Wednesday. The firm has a market cap of $198.40 million, a price-to-earnings ratio of -3.70 and a beta of 1.02. Inogen has a 52 week low of $6.14 and a 52 week high ...

Inogen posted a Q4 adjusted EPS loss of $0.24, beating estimates, with sales reaching $80.1 million versus the $73.9 million consensus. The company expects FY25 revenue of $352 million-$355 ...

Inogen beat Q4 earnings and revenue estimates, citing strong B2B demand. Analysts see potential but flag supply challenges and restructuring risks. Inogen, Inc. (NASDAQ: INGN) is well-poised for ...

GOLETA, Calif. (AP) — GOLETA, Calif. (AP) — Inogen Inc. (INGN) on Tuesday reported a loss of $9.8 million in its fourth quarter. The Goleta, California-based company said it had a loss of 41 ...

In a report released today, Michael Matson from Needham maintained a Hold rating on Inogen (INGN – Research Report). The company’s shares closed yesterday at $9.52. See what stocks are ...

For the quarter ended December 2024, Inogen (INGN) reported revenue of $80.08 million, up 5.5% over the same period last year. EPS came in at -$0.41, compared to -$1.14 in the year-ago quarter.

Although the revenue and EPS for Inogen (INGN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall ...